|
US5801195A
(en)
*
|
1994-12-30 |
1998-09-01 |
Celgene Corporation |
Immunotherapeutic aryl amides
|
|
PT780386E
(pt)
*
|
1995-12-20 |
2003-02-28 |
Hoffmann La Roche |
Inibidores de metaloprotease de matriz
|
|
US6747027B1
(en)
|
1996-07-22 |
2004-06-08 |
Pharmacia Corporation |
Thiol sulfonamide metalloprotease inhibitors
|
|
US6118001A
(en)
*
|
1996-08-07 |
2000-09-12 |
Darwin Discovery, Ltd. |
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
|
US6566384B1
(en)
|
1996-08-07 |
2003-05-20 |
Darwin Discovery Ltd. |
Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
|
|
EP0929519B1
(en)
*
|
1996-09-27 |
2005-02-23 |
PHARMACIA & UPJOHN COMPANY |
Beta-sulfonyl hydroxamic acids as matrix metalloproteinases inhibitors
|
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6133409A
(en)
*
|
1996-12-19 |
2000-10-17 |
Aventis Pharmaceuticals Products Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
IL155120A
(en)
*
|
1996-12-19 |
2008-06-05 |
Aventis Pharma Inc |
Process for the solid state synthesis of aldehydes, ketones, oximes and hydroxamic acids
|
|
US6392010B1
(en)
|
1996-12-19 |
2002-05-21 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and αβ-unsaturated carboxylic acid and aldehyde compounds
|
|
AU768182B2
(en)
*
|
1996-12-19 |
2003-12-04 |
Aventis Pharmaceuticals Inc. |
Process for the solid phase synthesis of aldehyde, ketone, oxime, amine, hydroxamic acid and alpha,beta-unsaturated carboxylic acid and aldehyde compounds
|
|
DE69829648T2
(de)
*
|
1997-01-22 |
2009-12-10 |
Aventis Pharmaceuticals Inc. |
Substituierte β-Thiocarbonsäure
|
|
BR9807824A
(pt)
*
|
1997-02-07 |
2000-03-08 |
Pfizer |
Derivados de n-hidróxi-beta-sulfonil-propionamida e seu uso como inibidores de metaloproteinases de matriz
|
|
ATE256107T1
(de)
*
|
1997-02-27 |
2003-12-15 |
Wyeth Corp |
N-hydroxy-2-(alkyl, aryl oder heteroaryl sulfanyl,sulfinyl oder sulfonyl)-3-substituierte alkyl, aryl oder heteroarylamide als matrix metalloproteinase als matrix metalloproteinase inhibitoren
|
|
US7115632B1
(en)
|
1999-05-12 |
2006-10-03 |
G. D. Searle & Co. |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
US6696449B2
(en)
|
1997-03-04 |
2004-02-24 |
Pharmacia Corporation |
Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
|
|
WO1998039326A1
(en)
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
|
|
IL131494A
(en)
|
1997-03-04 |
2005-06-19 |
Monsanto Co |
N-hydroxy 4-sulfonyl butanamide compounds and their use to prepare medicaments for treating conditions associated with matrix metalloproteinase activity
|
|
US6638952B1
(en)
|
1997-03-04 |
2003-10-28 |
Pharmacia Corporation |
Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
|
|
US6794511B2
(en)
|
1997-03-04 |
2004-09-21 |
G. D. Searle |
Sulfonyl aryl or heteroaryl hydroxamic acid compounds
|
|
WO1998039316A1
(en)
|
1997-03-04 |
1998-09-11 |
Monsanto Company |
N-hydroxy 4-sulfonyl butanamide compounds
|
|
AUPO721997A0
(en)
*
|
1997-06-06 |
1997-07-03 |
Queensland Institute Of Medical Research, The |
Anticancer compounds
|
|
US6300514B1
(en)
|
1997-06-25 |
2001-10-09 |
Ono Pharmaceutical Co., Ltd. |
Aryl (sulfide, sulfoxide and sulfone) derivatives and drugs containing the same as the active ingredient
|
|
CN1302206A
(zh)
*
|
1997-10-17 |
2001-07-04 |
阿温蒂斯药物制品公司 |
喹啉衍生物的治疗用途
|
|
RU2250105C2
(ru)
|
1997-11-14 |
2005-04-20 |
Дж.Д.Сёрл ЛЛС |
Ароматическая сульфонгидроксамовая кислота в качестве ингибитора металлопротеаз
|
|
US6750228B1
(en)
*
|
1997-11-14 |
2004-06-15 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
US20010039287A1
(en)
|
1997-11-14 |
2001-11-08 |
Thomas E Barta |
Aromatic sulfone hydroxamic acid metalloprotease inhibitor
|
|
ES2192349T3
(es)
|
1997-11-21 |
2003-10-01 |
Upjohn Co |
Derivados alfa-hidroxi, amino y halo de acidos hidroxamicos beta-sulfonilo utilizados como inhibidores de metaloproteinas matriciales.
|
|
US6288063B1
(en)
*
|
1998-05-27 |
2001-09-11 |
Bayer Corporation |
Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
|
|
DK1357109T3
(da)
|
1998-06-18 |
2008-09-08 |
Hoffmann La Roche |
Fremgangsmåde til arylalkylsulfid
|
|
FR2780402B1
(fr)
|
1998-06-30 |
2001-04-27 |
Adir |
Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
|
|
US6172064B1
(en)
*
|
1998-08-26 |
2001-01-09 |
Glaxo Wellcome Inc. |
Formamides as therapeutic agents
|
|
US6020358A
(en)
*
|
1998-10-30 |
2000-02-01 |
Celgene Corporation |
Substituted phenethylsulfones and method of reducing TNFα levels
|
|
WO2000044723A1
(en)
*
|
1999-01-27 |
2000-08-03 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors/tnf-alpha converting enzyme (tace) inhibitors
|
|
US6800646B1
(en)
|
1999-02-08 |
2004-10-05 |
Pharmacia Corporation |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
|
US6448250B1
(en)
|
1999-02-08 |
2002-09-10 |
G. D. Searle & Company |
Sulfamato hydroxamic acid metalloprotease inhibitor
|
|
US6583299B1
(en)
|
1999-05-20 |
2003-06-24 |
G.D. Searle & Co. |
α-amino-β-sulfonyl hydroxamic acid compounds
|
|
US6869951B1
(en)
|
1999-07-16 |
2005-03-22 |
Pharmacia Corporation |
Method of changing conformation of a matrix metalloproteinase
|
|
EP1671651B1
(en)
|
1999-08-21 |
2009-11-11 |
Nycomed GmbH |
Synergistic combination of pumafentrine and salmeterol
|
|
GB9922825D0
(en)
*
|
1999-09-25 |
1999-11-24 |
Smithkline Beecham Biolog |
Medical use
|
|
US6667316B1
(en)
|
1999-11-12 |
2003-12-23 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
GB9929979D0
(en)
*
|
1999-12-17 |
2000-02-09 |
Darwin Discovery Ltd |
Hydroxamic acid derivatives
|
|
US6699899B1
(en)
|
1999-12-21 |
2004-03-02 |
Celgene Corporation |
Substituted acylhydroxamic acids and method of reducing TNFα levels
|
|
US6326388B1
(en)
|
1999-12-21 |
2001-12-04 |
Celgene Corporation |
Substituted 1,3,4-oxadiazoles and a method of reducing TNF-alpha level
|
|
US6683093B2
(en)
|
2000-05-12 |
2004-01-27 |
Pharmacia Corporation |
Aromatic sulfone hydroxamic acids and their use as protease inhibitors
|
|
AU5652001A
(en)
|
2000-05-15 |
2001-11-26 |
Darwin Discovery Limited |
Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
|
|
US6506773B2
(en)
|
2000-05-15 |
2003-01-14 |
Darwin Discovery Ltd. |
Hydroxamic and carboxylic acid derivatives
|
|
FR2809623B1
(fr)
*
|
2000-06-05 |
2003-09-05 |
Sanjuan Benito Arranz |
Dans le traitement des maladies neurodegeneratives : (notamment alzheimer et parkinson), utilisation pour un medicament : du sildenafil (ou de ses derives)
|
|
US8030343B2
(en)
|
2000-06-08 |
2011-10-04 |
Celgene Corporation |
Pharmaceutically active isoindoline derivatives
|
|
US7312247B2
(en)
*
|
2001-03-27 |
2007-12-25 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US6495719B2
(en)
*
|
2001-03-27 |
2002-12-17 |
Circagen Pharmaceutical |
Histone deacetylase inhibitors
|
|
US7842727B2
(en)
*
|
2001-03-27 |
2010-11-30 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US8026280B2
(en)
|
2001-03-27 |
2011-09-27 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors
|
|
US6689794B2
(en)
|
2001-05-11 |
2004-02-10 |
Pharmacia Corporation |
Aromatic sulfone hydroxamates and their use as protease inhibitors
|
|
US6683078B2
(en)
|
2001-07-19 |
2004-01-27 |
Pharmacia Corporation |
Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
|
|
PE20030701A1
(es)
|
2001-12-20 |
2003-08-21 |
Schering Corp |
Compuestos para el tratamiento de trastornos inflamatorios
|
|
TW200406197A
(en)
*
|
2002-04-25 |
2004-05-01 |
Ono Pharmaceutical Co |
Therapelitic agent for inflammatory bowel disease containing hydroxamic acid as effective component
|
|
AU2003221786A1
(en)
|
2002-04-25 |
2003-11-10 |
Pharmacia Corporation |
Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
|
|
WO2003099272A1
(en)
*
|
2002-05-22 |
2003-12-04 |
Errant Gene Therapeutics, Llc |
Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
|
|
WO2004000811A1
(en)
*
|
2002-06-25 |
2003-12-31 |
Pharmacia Corporation |
Arylsulfonylhydroxamic acid and amide derivatives and their use as protease inhibitors
|
|
AU2003291097A1
(en)
*
|
2002-11-20 |
2004-06-15 |
Errant Gene Therapeutics, Llc |
Treatment of lung cells with histone deacetylase inhibitors
|
|
WO2004060346A2
(en)
|
2002-12-30 |
2004-07-22 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
US7135493B2
(en)
|
2003-01-13 |
2006-11-14 |
Astellas Pharma Inc. |
HDAC inhibitor
|
|
AU2004226353A1
(en)
|
2003-04-01 |
2004-10-14 |
Laboratoires Serono Sa |
Inhibitors of phosphodiesterases in infertility
|
|
DK1610678T3
(da)
|
2003-04-04 |
2011-10-24 |
Yeda Res & Dev |
Antistoffer til inhibering af aktiviteten af MMP-2 og MMP-9
|
|
US7244759B2
(en)
|
2004-07-28 |
2007-07-17 |
Celgene Corporation |
Isoindoline compounds and methods of making and using the same
|
|
EP1817020A4
(en)
*
|
2004-11-08 |
2012-11-21 |
Errant Gene Therapeutics Inc |
INHIBITORS OF HISTONATE ACETYLASE
|
|
ZA200806778B
(en)
|
2006-02-07 |
2009-11-25 |
Astellas Pharma Inc |
N-Hydroxyacrylamide compounds
|
|
WO2009008905A1
(en)
*
|
2007-02-01 |
2009-01-15 |
Panthera Biopharma, Llc. |
Hydroxamic acid derivatives of phenoxy-acetic acids and analogs useful as therapeutic agents for treating anthrax poisoning
|
|
US7807720B2
(en)
|
2007-02-01 |
2010-10-05 |
Panthera Biopharma, Llc |
Hydroxamic acid derivatives of 3-phenyl propionic acids useful as therapeutic agents for treating anthrax poisoning
|
|
KR20090113908A
(ko)
|
2007-02-23 |
2009-11-02 |
예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 |
금속단백질 활성 억제용 항체 및 이를 함유하는 약학적 조성물
|
|
WO2016128131A1
(en)
*
|
2015-02-09 |
2016-08-18 |
National And Kapodistrian University Of Athens |
Beta-lactone inhibitors of phospholipase a2 and uses thereof
|
|
CA3115038A1
(en)
|
2018-10-04 |
2020-04-09 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Egfr inhibitors for treating keratodermas
|